开放与腔内腹主动脉瘤修复术后早期再干预与高死亡率相关
基于NSQIP 2012至2014年5877例完整肾下腹主动脉瘤修复患者,开放修复组30天再干预率7.1%高于腔内修复组4.1%(P<.01)。再干预患者30天死亡率在开放组为28%对2.8%、腔内组为12%对1.0%(均P<.001),校正后再干预与30天死亡率独立相关(OR 13,95%CI 8-22,P<.001)。
要点
- 开放修复术后30天再干预率高于腔内修复(7.1%对4.1%,P<.01)。
- 再干预患者30天死亡率显著升高,开放组28%对2.8%,腔内组12%对1.0%。
- 校正混杂因素后,再干预与30天死亡率独立相关(OR 13,95%CI 8-22)。
核心结论
- 开放肾下腹主动脉瘤修复术后30天再干预率显著高于腔内修复,再干预与术后死亡率升高独立相关。
研究设计与样本
- 回顾性队列研究,查询美国外科医师学会NSQIP数据库2012至2014年所有完整肾下腹主动脉瘤修复患者,共5877例(开放修复658例,11%;腔内修复5219例,89%)。
- 30天再干预按当前操作术语(CPT)编码分类,采用Fisher精确检验和Mann-Whitney U检验进行单因素分析,逻辑回归识别再干预预测因素并评估再干预与死亡率的关联。
主要发现
- 261例患者接受再干预,开放修复组再干预率7.1%,腔内修复组4.1%(P<.01)。
- 再干预患者主动脉直径更大(中位数5.7 cm对5.5 cm,P<.01),就诊时症状更常见(16%对9.1%,P<.01),肾功能不全比例更高(7.7%对3.6%,P<.01),既往腹部手术史更多(32%对26%,P=.04)。
- 再干预患者30天死亡率更高:开放修复组28%对2.8%(P<.001),腔内修复组12%对1.0%(P<.001),主要并发症也更多。
- 与再干预显著相关的因素包括开放修复、直径、症状状态、高血压和肾功能不全。
- 校正人口学、合并症和修复类型后,再干预与开放及腔内修复后30天死亡率独立相关(OR 13,95%CI 8-22,P<.001)。
临床怎么用
- 腹主动脉瘤修复术后早期再干预提示预后不良,临床应重视再干预相关并发症的预防与管理。
- 开放修复术后再干预风险较高,可能与大动脉解剖复杂性和术者开放手术经验较少有关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Although reinterventions are generally considered more common after endovascular aneurysm repair (EVAR) than after open surgical repair (OSR), less is known about reintervention in the early postoperative period. Furthermore, there are few data regarding the impact of early reintervention on 30-day mortality. We sought to evaluate the rates and types of reintervention after abdominal aortic aneurysm (AAA) repair and the impact of reintervention on postoperative mortality. METHODS: The American College of Surgeons National Surgical Quality Improvement Program (NSQIP) was queried from 2012 to 2014 for all intact, infrarenal AAA repairs. The 30-day reintervention was classified by Current Procedural Terminology (CPT) codes. Univariate analysis comparing patients with and without reintervention was performed with the Fisher exact test and Mann-Whitney U test. Logistic regression was used to identify predictors of reintervention and to assess the association between 30-day reintervention and mortality. RESULTS: We identified 5877 patients (OSR, 658 [11%]; EVAR, 5219 [89%]), of whom 261 underwent reintervention (OSR, 7.1%; EVAR, 4.1%; P < .01). Patients who underwent reintervention had larger aortic diameter (median, 5.7 cm vs 5.5 cm; P < .01), were more often symptomatic at presentation (16% vs 9.1%; P < .01), and were more likely to have renal insufficiency (7.7% vs 3.6%; P < .01) and history of prior abdominal operations (32% vs 26%; P = .04). Patients who underwent reintervention had higher 30-day mortality (OSR, 28% vs 2.8% [P < .001]; EVAR, 12% vs 1.0% [P < .001]) and major complications. Factors significantly associated with reintervention included open repair, diameter, symptom status, hypertension, and renal insufficiency. After adjusting for demographics, comorbidities, and type of repair, reintervention was independently associated with 30-day mortality after EVAR and OSR (odds ratio, 13; 95% confidence interval, 8-22; P < .001). CONCLUSIONS: Compared with EVAR, patients undergoing open infrarenal AAA repair were significantly more likely to undergo 30-day reintervention, which could be related to higher open anatomic complexity and lower experience of the surgeon with open repair. Reintervention after both EVAR and OSR was associated with a >10-fold increase in postoperative mortality, emphasizing the need to minimize the complications associated with reintervention.
引用
- Deery SE, O'Donnell TFX, Bodewes TCF, et al. Early reintervention after open and endovascular abdominal aortic aneurysm repair is associated with high mortality. J Vasc Surg. 2017. PMID: 28943011. doi:10.1016/j.jvs.2017.06.104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。